SCHEMBL17993463

SCHEMBL17993463

c1ccc2c(c1)nc1c3ccccc3n3c4ccccc4nc3c3ccccc3n21

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.65
MAPT P10636 7/20 0.65
HSD17B10 Q99714 5/20 0.65
LMNA P02545 3/20 0.65
TP53 P04637 3/20 0.65
POLB P06746 3/20 0.65
ALDH1A1 P00352 8/20 0.62
HPGD P15428 6/20 0.62
KMT2A Q03164 5/20 0.59
MEN1 O00255 3/20 0.59
SMN1; SMN2 Q16637 3/20 0.54
NPC1 O15118 3/20 0.52
NFKB1 P19838 1/20 0.52
NFKB2 Q00653 1/20 0.52
RELA Q04206 1/20 0.52
TSHR P16473 3/20 0.49
BCL2 P10415 1/20 0.48
GAA P10253 1/20 0.48
HIF1A Q16665 1/20 0.48
CASP1 P29466 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL37035230 0.92 KDM4E (0.61) KDM4EMAPTHSD17B10LMNATP53
SCHEMBL10346630 0.92 KDM4E (0.61) KDM4EMAPTHSD17B10LMNATP53
SCHEMBL20821356 0.91 KDM4E (0.59) KDM4EMAPTHSD17B10LMNATP53
SCHEMBL861183 0.88 KDM4E (0.57) KDM4EMAPTHSD17B10LMNATP53
SCHEMBL19959757 0.85 KDM4E (0.54) KDM4EMAPTHSD17B10LMNATP53
SCHEMBL18057364 0.83 KDM4E (0.60) KDM4EMAPTHSD17B10LMNATP53
SCHEMBL21298154 0.83 KDM4E (0.51) KDM4EMAPTHSD17B10LMNATP53
SCHEMBL10023340 0.82 HPGD (0.54) KDM4EMAPTHSD17B10LMNATP53
SCHEMBL10023429 0.82 KDM4E (0.54) KDM4EMAPTHSD17B10LMNATP53
SCHEMBL10023428 0.82 KDM4E (0.54) KDM4EMAPTHSD17B10LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192714-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-06-22 US disclosed
US-20230192714-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-06-22 US disclosed
EP-3054498-B1 BISIMIDAZODIAZOCINES IDEMITSU KOSAN CO (JP) 2017-09-20 EP disclosed
WO-2016125110-A1 BISIMIDAZOLODIAZOCINES IDEMITSU KOSAN CO., LTD. (JP) 2016-08-11 WO disclosed
EP-3054498-A1 Bisimidazodiazocines Idemitsu Kosan Co., Ltd. (JP) 2016-08-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192714-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OCIAD2, OCIAD1, ODC1 KDM4E 2247/4885MAPT 1568/4885HSD17B10 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.